Nothing has changed with ISIS over the last month, yes it is facing some competition from AEGR but that is not new news. Kynamro is still on track with probable EMA approval as soon as Thursday (extremely likely). Normally, it is buy on expectations, sell on the news-- but ISIS has not moved much this week-- despite the upgrade. Based on the likely EMA approval we should be around $12 today, not just trying to break $9. Very odd. On top of that ISIS has over 26 drugs in the pipe line in the rare chance, EMA approval is not given--- which in an of itself brings value to at least $10. Oh well, I guess people have just not been followings ISIS, they will after approval on Thursday.